Related Experiment Video

Updated: Jun 4, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation

Yuji Kubota1, Pauline O'Grady, Haruo Saito

  • 1Department of Molecular Cell Signaling, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Tokyo 108-8639, Japan..

Nature Cell Biology
|February 22, 2011
PubMed

Insights

Oncogenic Ras drives cancer by activating the ERK pathway. It inhibits MEK SUMOylation, a process that normally downregulates ERK, thus promoting cell proliferation and malignant transformation.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cancer Research

Background:

  • The extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) cascade is crucial for mitogenic signaling.
  • Hyperactivation of the ERK pathway by Ras oncogenes is common in human cancers, but Ras's full role in carcinogenesis is not fully understood.

Purpose of the Study:

  • To investigate the role of MEK SUMOylation in regulating the ERK pathway.
  • To elucidate the mechanism by which oncogenic Ras influences MEK SUMOylation and ERK activation in cancer.

Main Methods:

  • Investigated MEK SUMOylation and its effect on ERK activation.
  • Examined the impact of oncogenic Ras on MEK SUMOylation using various cancer cell lines and mutations.
  • Assessed the role of MEKK1 as a SUMO-E3 ligase for MEK.

Main Results:

  • MEK SUMOylation downregulates the ERK pathway by disrupting MEK-ERK interaction.
  • Oncogenic Ras inhibits MEK SUMOylation, leading to enhanced ERK activation, cell differentiation, proliferation, and transformation.
  • MEK SUMOylation is abrogated in Ras-mutated cancer cells, with oncogenic Ras impairing MEKK1's ligase function.
  • Enhancing MEK SUMOylation suppressed Ras-induced cell transformation.

Conclusions:

  • Oncogenic Ras promotes carcinogenesis by activating the ERK pathway through both Raf activation and inhibition of MEK SUMOylation.
  • Targeting MEK SUMOylation presents a potential strategy for cancer therapy.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...